Bond.az - H.C. Wainwright reiterated a Buy rating and $50 price target for Legend Biotech Corp (NASDAQ:LEGN). The stock trades at $27.16 with a $5.04B market cap.
Analyst consensus is Buy, with targets from $27 to $86. The firm highlighted Legend's ASCO event on CARTITUDE and CARVYKTI (cilta-cel) with KOLs discussing durability at first relapse.
KOLs agreed CARVYKTI should be used at first relapse. Dr. Dhakal noted CARTITUDE-1 suggests a cure discussion, with one-third of patients progression-free beyond five years.
H.C. Wainwright maintains a $50 price target. Legend's revenue grew 56% over twelve months, and analysts expect profitability this year.
In recent news, Legend reported Q1 2026 EPS of -$0.15, missing estimates. The company also started a China Phase 1 study for LVIVO-TaVec400 in autoimmune diseases.
